Table 1.
Pharmacokinetic profile of bimatoprost acid in the aqueous humor and iris-ciliary body of New Zealand White rabbits following once- or twice-daily administration of topical bimatoprost 0.01% or dual fixed-combination bimatoprost 0.01%/brimonidine 0.1% ophthalmic solutions
| Topical ophthalmic solution | Dosage regimen | Aqueous humor
|
Iris-ciliary body
|
||
|---|---|---|---|---|---|
| Cmax (ng/mL) | AUC (ng⋅h/mL)a | Cmax (ng/g) | AUC (ng⋅h/g)b | ||
| Bimatoprost 0.01% | BID | 18.3±2.7 | 62.3±4.8 | 14.7±2.7 | 46.1±5.1 |
| QD | 13.9±1.8 | 42.8±3.1 | 15.0±2.8 | 31.5±3.0 | |
| Dual fixed-combination bimatoprost 0.01%/brimonidine 0.1% | BID | 12.9±3.0 | 49.4±7.4 | 13.5±3.0 | 42.9±6.6 |
| QD | 23.6±3.6 | 63.7±6.3 | 20.8±2.9 | 57.1±5.4 | |
Notes: Data are expressed as mean ± standard error.
a
AUC interval: 0–8 hours.
b
AUC interval: 0–6 hours, except in the bimatoprost 0.01% QD group (0–4 hours).
Abbreviations: AUC, area under the concentration-time curve; BID, twice daily; Cmax, maximum observed concentration; QD, once daily.